Best of ASCO - 2014 Annual Meeting

 

Welcome

Other GI Cancer

Gastrointestinal (Noncolorectal) Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Analysis of feasibility and survival in repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in appendiceal cancer with peritoneal dissemination.

Josh Karpes

e15702

Benefit of early-phase targeted, basket, and immune-based trials for patients with chemorefractory gastrointestinal (GI) cancers.

Rajiv Agarwal

e15700

Comprehensive characterization of pseudomyxoma peritonei.

Gabriel G. Malouf

e15701

Efficacy and safety of lanreotide 120 mg in the treatment of clinical symptoms associated with inoperable malignant intestinal obstruction (IMIO): Results from a phase II multicenter study.

Lionel Duck

4118

H3B-6527 clinical biomarker assay development and characterization of HCC patient samples.

Pavan Kumar

4121

Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.

Satya Das

4116

Molecular profile of ampulla of vater carcinoma (AVC): A rare tumor type with meaningful molecular alterations.

João Pinto

4119

Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial.

Alwin Krämer

4120

Prognostic value of the volume time index (VTI) ratio for patients with appendiceal cancer with peritoneal carcinomatosis treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

Josh Karpes

e15704

Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).

Richard S. Finn

4004

Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.

Joon Oh Park

4117